by Romain Magnez | Apr 10, 2025 | Publications
Vaxinano has the pleasure to present its latest scientific publication, “T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii”, recently published in BMC Infectious Diseases. This study...
by Romain Magnez | Feb 10, 2025 | Publications
Vaxinano is pleased to present its latest scientific publication, “Inactivated Toxoplasma gondii Nanovaccine Boosts T-Cell Memory Response in a Seropositive Yellow-Footed Rock Wallaby (Petrogale xanthopus) – A Case Report from Copenhagen Zoo”, published in the...
by Romain Magnez | Jan 10, 2025 | Publications
Improved ELISPOT protocol for monitoring Th1/Th17 T-cell response following T.gondii infection In the monitoring of human Toxoplasma gondii infection, it is crucial to confirm the development of a specific Th1/Th17 immune memory response. The use of a simple,...
by Romain Magnez | Dec 10, 2024 | Publications
Vaxinano is pleased to present the latest publication that our team contributed to: “Nanoparticles with a Lipid Core Can Enhance the Infection of Epithelial Cells with an Enterovirus”, published in Intervirology journal. This study explores the interaction between...
by Romain Magnez | Nov 12, 2024 | News
October 2024 – Today, Vaxinano announced an exclusive license agreement with Vetoquinol to develop its leading canine leishmaniasis vaccine candidate using Vaxinano’s proprietary nanoparticle technology. The terms of the agreement were not disclosed but include...
